Olaparib

我们是谁

• 2022 年 4 月 5 日

  The Drug Rediscovery Protocol (DRUP Trial)

• 2022 年 4 月 5 日

  Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors

• 2022 年 4 月 5 日

  Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).

• 2022 年 4 月 5 日

  Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can…

• 2022 年 4 月 5 日

  Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

• 2022 年 4 月 5 日

  TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer